Clinical Trial Update: Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a combination of venetoclax, a hypomethylating agent, and low-dose cytarabine as salvage therapy for relapsed or refractory acute myelo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Cytarabine (Low-Dose) (cytarabine)
• Hypomethylating agent
• Venetoclax (venetoclax)

Snippet

Sponsor: Beijing 302 Hospital | Conditions: Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 2 | Status: UNKNOWN